Erasca, Inc.

ERAS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020
Operating Activities
Net Income $-124.5M $-161.7M $-125.0M $-242.8M $-122.8M $-101.7M
Depreciation & Amortization $3.1M $3.8M $3.7M $2.6M $829.0K $540.0K
Depreciation
Amortization
Stock-Based Compensation $24.9M $27.0M $26.2M $20.1M $8.3M $797.0K
Net Cash from Operating Activities $-95.5M $-109.4M $-101.2M $-103.3M $-79.6M $-32.7M
Investing Activities
Capital Expenditures $128.0K $60.0K $1.8M $14.6M $11.2M $947.0K
Business Acquisitions
Net Cash from Investing Activities $100.4M $-156.6M $-91.2M $-71.1M $-64.6M $-71.2M
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $1.1M $240.7M $1.3M $98.1M $439.4M $140.0M
Net Change in Cash $6.1M $-25.3M $-191.1M $-76.3M $295.2M $36.1M
Free Cash Flow $-95.6M $-109.5M $-103.0M $-117.8M $-90.8M $-33.6M